BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates [Yahoo! Finance]
BioLineRx Ltd. - American Depositary Shares (BLRX)
Last biolinerx ltd. - american depositary shares earnings: 5/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.biolinerx.com
Company Research
Source: Yahoo! Finance
- Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem cell transplant procedures performed - on track to reach stated goal of ~35% by end of Q2 Announced new data in abstract accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on pilot phase of ongoing Phase 2b pancreatic cancer clinical trial collaboration with Columbia University - Collaboration partner Gloria Biosciences' motixafortide HSC mobilization bridging study IND was filed and approved by the Center for Drug Evaluation of the National Medical Products Administration in China . Anticipate clinical trial initiation 2H 2024 - - Completed debt and equity financing totaling $26 million to support U.S. commercialization of APHEXDA and advance lifecycle expansion activities - Management to host conference call today, May 28 , at 8:30 am EDT TEL AVIV, Israel May 28, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLR
Show less
Read more
Impact Snapshot
Event Time:
BLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLRX alerts
High impacting BioLineRx Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLRX
News
- BioLineRx Ltd. (NASDAQ: BLRX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- BioLineRx stock jumps 14% on St. Jude clinical trial for mitoxafortide [Seeking Alpha]Seeking Alpha
- BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) [Yahoo! Finance]Yahoo! Finance
- BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)PR Newswire
- BioLineRx Ltd. (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
BLRX
Earnings
- 5/28/24 - Beat
BLRX
Analyst Actions
- 5/29/24 - HC Wainwright
BLRX
Sec Filings
- 6/18/24 - Form 6-K
- 5/30/24 - Form 6-K
- 5/28/24 - Form 6-K
- BLRX's page on the SEC website